Hunterbrook Media issued a report on Hims & Hers this morning and noted that based on its reporting, Hunterbrook Capital is short the stock. Hims & Hers sells knockoff GLP-1 weight loss drugs through a loophole that could end at any time, Hunterbrook’s Sam Koppelman, Matthew Termine and Michelle Cera report. The journalists say Hims & Hers relies on a sole GLP-1 supplier “with previously unreported ties to fraud and bankruptcy. They note that a Hunterbrook Media reporter qualified for GLP-1 knockoffs from Hims after a four-minute survey, then got a prescription without speaking to a doctor or submitting medical records. The company could suffer legal liability if GLP-1 knockoffs prove unsafe, ineffective, or violate a patent, according to an FDA legal expert, adds Hunterbrook. Hims & Hers shares are down 3% to $21 following the report.
previous post